-
New medication for the treatment of advanced pancreatic cancer increases median overall survival from 6.7 to 13.2 months.
Medical Mythbusting Commentary for June 1, 2026 Source:‘I actually started crying’: Oncologist reacts to pancreatic cancer drug results Synopsis of the article and study: Benefits: Doubled survival, oral convenience, targeted action, manageable side effects. Limitations: Grade 3+ adverse events in about one-third of patients; still experimental, not yet fully approved; tested in advanced cases post-chemo.
-
Observational study noted that patients with diabetes and obesity using GLP-1 medications may experience reduced degree of metastases. Causality confirmation and mechanisms to be determined.
Medical Mythbusting Commentary for May 25, 2026 Source:GLP-1 Users May Experience A Surprising Life-Saving Benefit That Has Nothing To Do With Weight Loss
-
It stands to reason that most medications designed to manage progressive chronic disease once discontinued will see a relapse or progression of said disease process.
Medical Mythbusting Commentary for March 25, 2026 Source:Stopping GLP-1 drugs like Ozempic erodes heart health benefits quickly, new study finds Reference:GLP-1RA discontinuation and risks of major adverse cardiovascular events in adults with type 2 diabetes: A target emulation trial.
-
Oral version of injectable cholesterol-lowering medication completes phase 3 trial with noted reductions in LDL-cholesterol as well as lipoproteins.
Medical Mythbusting Commentary for February 9, 2026 Source:Experimental cholesterol-lowering pill may offer new option for millions Reference:A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide
-
Likely many factors behind increase in ADHD medications in Ontario.
Medical Mythbusting Commentary for December 12, 2025 Source:Dramatic rise in number of people going on ADHD medications in Ontario, with one group leading the sudden increase Reference:Population-Level Trends in Attention-Deficit/Hyperactivity Disorder Medication Prescribing
-
Health Canada approves first pill to reverse postpartum depression withing days of starting it.
Medical Mythbusting Commentary for December 10, 2025 Source:Health Canada approves 1st pill to treat postpartum depression
-
Climate pollution from inhalers has the impact of half a million cars per year, or 0.03% of global CO2 equivalent emissions, study finds. The latter number provides some perspective.
Medical Mythbusting Commentary for October 14, 2025 Source:Climate pollution from inhalers has the impact of half a million cars per year, study finds Reference:Inhaler-Related Greenhouse Gas Emissions in the US; A Serial Cross-Sectional Analysis Question: The study showed that In one year alone, planet-warming pollution from inhalers were the equivalent of driving more than half…
-
Cannabis-derived medication for the treatment of chronic low back pain seeks licensing approval in the U.S. and Europe
Medical Mythbusting Commentary for October 1, 2025 Source:A drug made from marijuana reduced back pain in a large study
-
New medication in the research pipeline designed to improve upon the efficacy of semaglutide and tirzepatide (Ozempic and Mounjaro) and mitigate side effect profile. Still years to go.
Medical Mythbusting Commentary for September 11, 2025 Source:Scientists create new drug that could be the ‘next Ozempic’… it’s twice as effective without nasty side effects